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Until recently, tr~ns~l~~~~tion nnd organ ~r~~~ure~~~~nt cf- 
forts in the United States of America were pearly orguniaed. 
Uniform A~~t~rn~~~l Gift Act of 1 form~li%ed a 
ensus definition of brain de~rh and paved the way for 
d~n~~t~on of solid organs ( IL Actual organ ~ro~urem~~t 
and d~st~but~on, however, remained 1 ely the r~s~onsibil~ 
ity of i~ividu~~ tnnspiant centers a informal consortia 
until the early 1980s. Computer systems, such as those 
by the North American Transplnnt Coordinators 
ion (NATCB), the Southcsstern Organ Prc)cure- 
rnent Foundation (SE6PF) and the Southwest Organ Bank 
#+KIB), facilitated the regional ~ro~ur~rne~~t and distribu- 
tion of organs, These voluntary regional ~~rn~uteri~~d net- 
works were initially adequate but evenruatty proved inuuffi- 
cient to meet the national need spurred by ~rn~r~~ven~~nts in 
-+?rm reservation when hearts could be preserved for 
h h and long distance p~~~~~rn~nt hrcnme a reality. 
sptantation for all solid 
nt and t~sp~~~t~tion. and for a 
and T~s~~~tati~ Network and 
continuing maturity of UNOS eased 
vofuntaty organization. Because of its 
tment o organ procurement, UNOS was 
to establish and operate the 
~~stern~~t~~~l~~ collect donor and resilient data for 
quality control, 
a ~~a~~~t~~~n the professional skills of those involved in 
organ ~~o~~~e~~~~t and transpl 
Both th: 8rgao ~r~c~~~~~~~~~t a 
work :tnJ the ~~ient~~~ Registry are under the a~rni~istr~~t~o~ 
of the Division of Brgan Trans~~antatio~~ a division of the 
lie&h Resources and Services AdI~inislration, which is 
within the ~~~rtrnent of Health and ~~~rna~ Services. 
~~~$ ~~inta~~s a national computerized list of patients 
waiting for kidney, heart. heartmtung. lung, liver and pan- 
creas transplants. An ‘Qrgan Center” number allows 24-h 
access to the computer system by all transplant programs in 
the W,S. The Scientific Registry collects and maintains data 
pertaining to patients waiting for transplants, donors, recip- 
ients of donated organs, donor-recipient matching and organ 
allocation. and donor-recipient histocompatibility (2). 
Iieart transplantation was performed regularly in only a 
few centers before 1980, The adverse publicity that initially 
followed the unbridled zeal of the many surgical teams 
performing this operation, which typically bad an abysmal 
outcome between 1968 and 1970 (3), resulted in substantially 
diminished clinical activity that was limited to a few centers 
with reasonable success rates during the 1970s. However, by 
1980, improvements in immunosuppressive therapy and sci- 
entifia a~bisvs~~~n~s in I Grst~~lldio~ f ~lll6~~~df~ phys-
e of and ability to 
tion r~s~~~t~d in a renew ~~1~~~~~~ ia hcxl t 
The eu~~~~ra~iu~ prclimi ry results lhat follow 
ration of ~y~~osQor~~~ into im 
1980 (4) further served as a muhls for deve~QQme~~t Qf 
heart transplant programs. Addit~oaa~ly, third-party payers 
were soon IQ accept the procedure as established therapy 
and reimburse accordingly. As a result, the number of heart 
cedures performed annually increased from 62 
27 in 1991 according to data corn 
perative ~~d~sQl~~~tatio~ Study ( 
During that same period, the number of transplant centers in 
the U.S. rose from 8 to 1156, avc:raging, however. only 13.6 
transplants annually per center (Fig. 2). Considerable vari- 
ability exists in the heart transplantation activity at individ- 
ual iusiiiutions (Table I); 43 Qerccnt of the: 1% f~iii~Siht 
centers performed <!O transplantations a year and 17 cen- 
ters performed 36.7% of all transQ~aut procedures. 
observers question whether low volume centers s 
e or financially survive, and discussion of the pros 
a of re~~oaa~i~~u~ the availability of this procedure, 
both to ensure institutional excellence and allow Mars” 
meaningful Qlospective clinical trials, is ongoing. 
Figure 2. Number of heart transplant progrgklns in the United States, 
I981 to 1991. 
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criteria have already been initiated. 
hearts with longer ischemic times, t 
function are being co~si~~r~d in etTort to increase donor 
volume. Additio~la~~y, further e ts at 
coordinators are needed to reduce the comber 
the need for heart 16, 
55 years are considered, with a ~~rarna~i~ 
increase to >40 when patients between 55 and 65 years 
arc ad&d to the pool (Fig. 3). These estimates are c~~siste~~ 
Year 
IQ 
ayo Clinic (8). Although heart 
Id benefit M_WOO people annually in 
donors will be available by the most 
tes just noted. Although not every 
o dies of heart disease would be a good transplant 
it is clear that there is a gross disparity between 
donor supply and the potential demand that would not likely 
ever be met even with the most optimal use of the donor 
supplY. 
tive to that ofother 
-23). ~~f~~tu~~tel~, most 
o provide the service, 
debate about health c 
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compared with relevant corn~~ti~~ medical and su 
therapies (9.1 l-16,24). Various ~~~~cial assents of 
Nation were ex~~mined in the ~~tiQn~I ~~~op~r~~tive 
lantation Study, a federally funded study, in which 
of all heart transplant programs in the U.S. pnrtici- 
pated (5,241. In this study, itemized traan 
ned from I r~nd~rn s 
in calender year 1988. Data on ~ctuaI 
t ~v~l~blc for analysis. 
native T~nsplantation Study con- 
chaise category, the range was considerable, 
the use af medians rather than means as I 
ncy. Data on total heart transplant 
of initial discharge, are 
As shown, the average 
arges and length of stay in the 
Total transplant charges varied according to several fac- 
tors (27). For example, patients aged ~18 years incurred 
higher charges than did patients aged 318 years. Retrans- 
plant p~edu~s were more costly than primary grafts. 
Charges for patients wha required an artificial device for 
cardiac support or as a bridge to transplantation were much 
higher than for those who did not. Patients on life support or 
in inlcnsivr care bcfcwe tr;lnspl~~nll\tiull incurred much 
lrigher charges from the date of ~~~~r~~ti~~~~ tban did pnticnts 
\VbQ were l~~§~~t~~l~~e outside the intWsiVt CirK! unit or iii 
home, Also. charges for ~~~~tie~~ts who stlrvive~~ for I year 
were less than for those who did not and the shorter the 
length of stay, the lower the charges. 
rititig Period 
U~fort~oately. the waiting time for an appropriate donor 
once a patient has been listed as a heart transplant recipient 
has increased markedly over the past decade. The median 
wait for a donor heart of ==I month in 19gQ increased to 
186 -C 7.9 days in 1990 (2). Twenty-nine percent of patients 
listed for transplantation in 1990 waited 6 months to I year 
and 20% waited > I year before a donor organ was identified. 
For at least the past I2 months more patients were listed on 
any given date than underwent transp~al~tatiol~ in the previ- 
ous year, reflecting the severity of the crisis (Fig. 5). 
The current method of reporting outcome for heart trans- 
plantation is based on survival from time of transplantation. 
A more meaningful analysis would be survival from the time 
the patient is listed for transplantation. Such data would 
better present the true utility of this procedure. 
Reliable information about the death rate and contribut- 
ing risk factors in patients accepted for and awaiting 
heart transplantation is limited. The most accurate cur- 
rent information is contained in the UNOS 1990 Annual 
Report of the Scientific Registry (2). Even this information is 
only an approximation, beccluse during this time period 
UNOS had direct knowledge of a death on the waiting 
list on/y if the reported reason for removing a patient 
from the computer list was coded as “death.” Thus, patients 
who were removed from the waiting list for other reasons 
and subsequently died would not have been included in the 
death analysis. The calculated death rates therefore under- 
estimate the actual death rates on the waiting list. For the 
years 1988 through 1990, nearly 20% of patients on the 
waiting list died before transplantation. Although the pro- 
category of status 1 
wn rncreased ris 
c~)ril~llteri~cd waiting list. 
mm 1 the currcnt IJNOS organ ~~~~(~cat~(~~~ 
~ltie~~t-4~~ve~ system that strives for a 
distr~b~t~o~ of organs to potential ret 
waiting time and their likelihood of deat 
tion can be performed. Such a system wou 
abundance of transplant centers (>SO% pe~or~l~ag < I4 trans- 
plant procedures a year), thetc is intense competition among 
centers for suitable organs for their own patients awaitin 
tr~~l~splal~tati~)n, In this etiviroliliic~lt~ it is critically im~ort~~n6 
that any allocation sckcme must be l~o~~t~yrcd so that abuse or 
misuse of the system for individual i~stit~t~~a~~l gain can be 
identified and corrected. Only in this way can all ~tients be 
given fair access to cardiac transplantation. 
Greater access to the already existent potential donor 
organ pool could in fact substantially increase the number 
of transplant procedures performed annually in the U.S.: 
however, ~~,O~ cardiac organ donors a year will never 
be available. as noted, above. The high mortality rate of 
patients on the transplant waiting list will be a~ected only 
by improved treatment of congestive heart failure (which 
will also reduce the need for transplantation) or by alterna- 
tives to cardiac allotranspla~tatio~~ as is described in Task 
Force 6. 
The current m~lti~~~st~tuti~~~al survival data Co 
are available from two sources: the 1990 Annual 
the U.S. Scientific Registry for Organ Transpla 
which includes patients undergoing transpla~tat~ 
October 1987 and December 31. 1989, and the 
12 O’CONNELL ET AL. 
TASK FORCE 1 
JACC Vol. 22. No. 1 
July 1993: 1-64 
Cardiology Research Database, which analyzed survival and 
examined risk factors by multivariate analysis in patients 
undergoing primary heart ransplantation in 25 high volume 
U.S. transplant institutions between January 1990 and June 
1991 (29). Overall reported l-year patient survival after 
transplantation n the U.S. is between 81% and 84% (229). 
One-year survival is slightly higher among white (82%) than 
among black (78%) or Hispanic (79%) transplant patients. 
There was no important difference in survival by recipient 
blood group in the UNOS analysis and male recipients had a 
slightly higher I-yc@r survival rate (82.5%) than did female 
recipients (80%). 
Of particular note in the UNOS analyses was the important 
impact (evaluated by univariate analysis) of prior transplanta- 
tion and patient age and status at the time of transplantation on 
l-year survival. Patients undergoing heart retransplantation 
had a l-year survival rate of only 56% compared with 82% for 
those undergoing primary transplantation. In this analysis, 
however, the indication and patient condition at the time of 
retransplantation were not specifically analyzed. 
By univariate analysis, very young patients (~5 years of 
age) had a 72% l-year survival rate, compared with 82% to 
84% for patients aged 6 years to 64 years. Survival was 
intermediate (79%) in patients >65 years old. A multicenter 
registry of retransplantation identified accelerated coronary 
artery disease and retransplant i erval >6 months as inde- 
pendent predictors of lower mortality rate (30). 
In the UNOS analysis of survival after primary transplan- 
tation, detailed information is not available relating to the 
current patient urgency status codes. However, the analysis 
included six patient categories, ranging from outpatients who 
were working full time preoperatively to those who were 
seriously ill and on life support. Only patients on life support 
(which included ventilator, intraaortic balloon pump or left 
ventricular assist devices) had a diminished (74%) l-year 
survival rate. All other patient categories, including those in an 
intensive care unit, had a l-year survival rate >80%. 
BY multivariate analysis, the Transplant Cardiology Re- 
search Database analysis dentified very young recipient age, 
advanced recipient age, ventilator support at time of transptan- 
tation, lower pretransplantation cardiac output, higher pulmo- 
nary VaSCdar resistance in children, longer donor ischemic 
time, older donor age and donor and recipient non-0 blood 
group as risk factors for death during the study period (29). 
insurance Coverage and Reimbursement 
Insurance coverage for medical and surgical therapies i  
increasingly subjected to cost-effectiveness considerations. 
For example, the Health Care Financing Administration 
(HCFA) recently published draft guidelines for the evaluation 
of new medical technologies (31,32) that included an analysis of
cost-effectiveness. The HCFA approach will surely influence 
the private insurance community, which is also attempting to 
come to grips with increasing health care expenditures. 
Medicare currently covers heart transplants for eligible 
beneficiaries based on a variety of patient selection criteria, 
coupled with restrictions on which transplant centers are 
eligible for reimbursement (15,20,23,24,27,28,33). The latest 
survey of Medicaid programs revealed that 78% of the states, 
including the District of Columbia, covered heart ransplanta- 
tion (34). Finally, from Health Insurance Association ofAmer- 
ica data from 1988, it appears that about 84% of commercial 
insurers pay for heart ransplants (35). Similar data are not 
available for the Blue Cross and Blue Shield Association. Each 
plan operates independently. In 1988, 1,647 heart ransplant 
procedures were performed by 141 programs in the U.S. Of 
these procedures, 7% were paid for by Medicare, 6% by 
Medicaid programs and 87% by other payers (24). 
Data from the National Cooperative Transplantation 
Study indicate that underrecovery of charges is a problem 
for many heart transplant centers. For 11% of the proce- 
dures studied, between 0 and 20% of charges were recov- 
ered. For 10% of the procedures, between 21% and 60% of 
charges were recovered. For 7% of the procedures, between 
61% and 80% of charges were recovered. Finally, for 72% of 
the procedures tudied, reimbursements were >80% of 
charges (24,27,28). 
Qualijcations of Transplant Centers 
Both public and private insurers have made decisions 
with dramatic implications for the provision of transplanta- 
tion services in the U.S. In our current system of health care 
these insurers can and do decide not only what particular 
medical services they will pay for but, increasingly, who or 
which institution they will pay to provide the services. The 
outcome of this “medical market economy” in terms of 
patient access to transplantation services requires careful 
scrutiny. In the field of transplantation, clinical centers must 
qualify not only for insurer reimbursement but also for 
access to donor procurement services, and the quaiiiication 
criteria may vary widely. 
To date, the criteria for proficiency that have been 
specified for heart transplant programs have been mainly 
criteria for institutions or programs rather than for individ- 
uals. Such criteria were first specified by the HCFA and 
subsequently b several third-party payers and include des- 
ignations for required program volume, patient survival rates 
and patient selection criteria, as well as requirements for 
participation i au organ procurement progiarn and ade- 
quacy of various laboratory services. Such criteria re used 
to designate centers that the third-party payer agrees to 
reimburse for performing transplant prccedrres on the pay- 
er’s subscribers. 
Increasingly, insurers are contracting with selected centers 
for transplant services (36-42) to control their costs and ensure 
quality (42). Ahhough this concept is viable, it is clear that 
patient access to transplant services in insurance-controlled 
systems can be a problem. Patients may be forced to travel 
great distances for their transplant procedure. Also, transplant 
centers compete on the basis of an unknown profit margin 
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em also include requirements 
ram. According to their requirements, a tboracic 
on mnst be board certified or eligible and 
tive bemody~amic care, ostoperative imm~~os~~~ressive 
therapy and outpatient foil -up. ‘Transplant physicians for a 
thoracic organ program ust be board certified or eligible in 
their specialty 
experience, d 
chronic heart failure, donor seiectiol:, use of mechanical assist 
devices, recipient selection, preoperative and postoperative 
hemodynamic care, postoperative immunosuppressive tber- 
apy, histologic nterpretation and grading of myocardial biopsy 
specimens for rejection, and long-term outpatient follow-up. 
Separate criteria have been established for pediatric heart 
transplant personnel. 
Although standards of excellence are clear!y needed to 
ensure the provision of a uniformly high quality of transplant- 
related care and to discourage the continuaticln of low quality 
programs, several caveats need to be made regarding the 
currently specified criteria for funding (and thus viability) of 
transplant programs. Standards orminims levels for tra~s~la~~ 
program volume (Oi ,.,_- nannbers of transplant procedures a year) 
are perhaps the least controversiai ofthese. They vary accord- 
ing to the type of recipient (pediatric vs. adult), but mosi 
insurers require hospitals to perform a minimum of 6 to 12 
procedures annually. Few would argue that some continuing 
volume of experience is necessary to maintain the skills of 
those involved with clinical care, and the standards have been 
set intentionally on the low side. 
Standards ofexcellence for heart mnspht program sur- 
vival rates also seem inherently sensible, but the exact level at 
which the standard should most sensibly (or equitabiy) be set 
can be controversial. If survival rates or oiltcomes as such are 
viewed as the main standard of quality ibr a program, there 
woulrl be a strung negat& incentive Poward accepting any high 
risk patients (unfavorable patient mix), and centers that did so 
could be penalized. Conversely, survival rates below a certain 
Ieitel could be agreed to be uaacceptable. A compromise might 
be indexing survival rates according to the estimated preoper- 
ative risk of the patient, although quantihcation f such risk 
status till would be an inexact estimate. 
Perhaps the program gnalification most difficult o judge 
or evaluate is the more easily quantifiable one of expendi- 
insurer contracting leads to limitation of both the ~~rnbcr 
n of qualified centers, tient access to trans- 
patient choice of pro 
sarily constrained. Transplaut 
adm~~~st~tors are wary 
attempts to ration care 
of transplant services i  tbat 
of t$a~s~~a~t cen ers. Although many decrie 
ch cked proliferation ofcenters in the 19gOs, 
quite wary of allowing insurers to decide iss 
quality or distribution ofmedical care, even if their 
1. Given the institutional resources ~eq~~ed a 
currently limited donor availability, the College sho 
knowledge that there is an overabundance of heart trans- 
plantation centers in the U.S. The ~eve~o~me~t of new 
rograms and co~ti~~at~o~ of existing programs should be 
ependent on regional/societal medical needs. 
2. UNOS has played asignificant role in the 
and delivery of transplant services in the U.S. 
mend that the College active!y support UNOS 
3. In recognition ofregional variations inheart ranspla 
need and donor supply, we encourage insurers that design 
transplant centers to do so with appropriate geo~a~~ic 
distribution, thereby facilitating patient access. 
This Conference endorses: 
8 Clinical trials directed to the treatment of congestive 
heart failure focusing on alternative thera$es for pa- 
tients currently awaiting heart ransplantat‘un. 
ograms designed to maximize donor uti!: ation. 
ploration of models of presumed cc:%ent as a 
method of increasing donor availability. 
B As part of transplantation utcome analyses, the re- 
porting of survival and other events according to intea- 
tiorr to treat-that is, with the time of initial entry onto 
the wait list as “time zero”-to ahow assessment of 
risk factors for pretransplant morbidity and mortality. 
ation of variables, 
of methods that all 
tion to compare institutions ex 
recipient subsets most likely to t from heart rans- 
plantation. 
Studies that examine the actua! cost of, in addition to 
charges for, transplantation a d related activities. 
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Establishment of criteria for the evaluation of heart 
transplant centers by examining risk-adjusted survival, 
relative cost and experience. 
Studies of cost-effectiveness of heart ransplantation rel-
ative to that of other medical nd r;rgicd procedures. 
Development of uniform standards for heart ransplant 
program resources and excellence, agreed on by profes- 
siona’rs within the field and insurance carriers, that could 
be generally recognized and could guide insurers to 
“designating” or reimbursing care at quality programs. 
Development of a methodology for physician reim- 
bursement reflecting the time intensity and overhead of 
transplant physicians and surgeons. 
Development of criteria for formal postgraduate and 
fellowship training in pediatric and adult heart ransplan- 
tation within qualified centers, consistent with national 
needs. 
e Continuing medical education programs directed to 
practicing cardiologists with respect o the recipient 
selection, donor manirgement (heart and lung) dnd 
follow-up care of the transplant recipient. 
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